All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
On July 6, 2020, the U.S. Food and Drug Administration (FDA) lifted the partial clinical hold on the phase II clinical trial of camidanlumab tesirine in patients with relapsed or refractory (R/R) Hodgkin lymphoma (HL).
Camidanlumab tesirine is an anti-CD25 antibody-drug conjugate which is being evaluated for patients with R/R classical HL (cHL). At the 15th International Conference on Malignant Lymphoma (ICML), the lymphoma hub spoke to Graham Collins, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, who reported the results of the phase I trial (watch the video here).
The pivotal phase II (NCT04052997) multi-center, open-label, single-arm clinical trial is evaluating the safety and efficacy of camidanlumab tesirine in patients with R/R cHL. Patients with R/R cHL who failed three previous lines of therapy including brentuximab vedotin and a checkpoint inhibitor approved for cHL (e.g. nivolumab or pembrolizumab) were eligible for the study. Patients already enrolled in the trial continued to be treated during the partial clinical hold, and now that the hold has been lifted, additional patient enrolment can resume.
The study is expected to support the submission of a Biologics License Application to the FDA.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox